50% cheaper price! Eli Lilly's best-selling weight loss drug Zepbound launches small bottles
王俊杰2017
发表于 2024-8-28 13:19:25
141
0
0
Lilly recently announced that the company has launched and sold the best-selling weight loss drug Zepbound in small bottles of 2.5mg and 5mg single dose tirzepatide in the United States to meet the growing demand. Patients can buy the two specifications on Lilly's self operated website "LillyDirect", with monthly fees of $399 and $549 respectively. Compared to the price of all other GLP-1 drugs used to treat obesity, the price of single dose vials can enjoy a 50% or higher discount, and this new option helps millions of obese adults get the medication they need.
A research report shows that although cost reduction may lower the average selling price of Eli Lilly Zepbound in the short term, the additional sales of bottled drugs "may have a positive impact on Eli Lilly's sales performance".
From the current situation, the main market share of GLP-1 drugs worldwide is occupied by Novo Nordisk and Eli Lilly. According to Pfizer's forecast, GLP-1 receptor agonists in the US market alone will generate $50 billion to $55 billion in revenue for weight loss indications by 2030. Considering that the weight loss indication of Tilpotide has been approved for market in November 2023, and that Eli Lilly and Novo Nordisk continue to expand production capacity, Goldman Sachs' analysis team has raised the global weight loss drug market size from $100 billion at the end of last year to $130 billion by 2030.
Recently, Eli Lilly released its financial performance for the second quarter of 2024, which greatly exceeded market expectations. Lilly's revenue for the second quarter was $11.3 billion, a year-on-year increase of 36%. This is mainly due to the contribution of Mu Fengda (Mounjaro – type 2 diabetes indication, Zepbound – long-term weight management indication) and alternative. Excluding the $579 million revenue from the sale of Baqsimi (glucagon nasal powder) equity in Q2 2023, Q2 revenue increased by 46% year-on-year; The revenue of non intestinal glucagon drugs increased by 17% globally and 25% in the United States.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Sales of "weight loss pills" are booming, and Novo Nordisk's performance has reached a new high
- Tesla Loses, Xiaomi's Hot Selling Car Market Meets a New Pattern, NIO and Xiaopeng Lead the Decline Today
- Top 20 US Stock Exchange Transactions: Tesla Cybertruck Retains as the Top Selling Model in the United States with a Sales Volume of Over $100000
-
9月が終わり、映画・テレビ業界が暗躍している。最近、愛奇芸の創始者でCEOのGONG宇氏は、映画・テレビ業界が長短の変化、AIの変化、中国映画・テレビドラマの海外進出の変化の3つの変化を経験していると発表した。 ...
- 寒郁轩良
- 8 小时前
- 支持
- 反对
- 回复
- 收藏
-
8月のトヨタ自動車(ダイハツ自動車と日野自動車を除く、レクサスを含む)の世界生産台数は前年同月比11.2%減の709571台、世界販売台数は前年同月比3.1%減の826863台だった。 日本本土市場では、トヨタ自動車の8月 ...
- SOGO
- 前天 18:03
- 支持
- 反对
- 回复
- 收藏
-
ネットワーク状況監視サイトDownDetectorによると、オーディオストリーミングプラットフォームSpotifyは日曜日に約3時間にわたる障害を経験した後、正常に回復し、ピーク時には米国の4万人以上のユーザーに影響を与 ...
- hecgdge4
- 13 小时前
- 支持
- 反对
- 回复
- 收藏
-
百済神州(688235.SH)はA株の有名な革新薬企業で、2017-2024年上半期、同社の各期の研究開発投資はA株の化学製薬会社(申万二級)の中で最も高く、研究開発費用は合計600億元を超えた。 しかし、百済神州にとって ...
- wylz8473
- 昨天 18:36
- 支持
- 反对
- 回复
- 收藏